Invitae (NYSE:NVTA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Invitae (NYSE:NVTA) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the medical research company’s stock.

Invitae Price Performance

Shares of NVTA opened at $0.00 on Tuesday. Invitae has a 1 year low of $0.02 and a 1 year high of $0.02. The company has a market cap of $106,804.00, a price-to-earnings ratio of 0.00 and a beta of 1.59.

Institutional Investors Weigh In On Invitae

Institutional investors have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC grew its holdings in shares of Invitae by 404.6% in the third quarter. Janney Montgomery Scott LLC now owns 63,105 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 50,600 shares in the last quarter. Financial Gravity Asset Management Inc. grew its holdings in shares of Invitae by 1,799.5% in the third quarter. Financial Gravity Asset Management Inc. now owns 73,929 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 70,037 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Invitae by 90.7% in the fourth quarter. SG Americas Securities LLC now owns 91,937 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 43,717 shares in the last quarter. Pathstone Family Office LLC grew its holdings in shares of Invitae by 94.2% in the third quarter. Pathstone Family Office LLC now owns 157,972 shares of the medical research company’s stock valued at $96,000 after purchasing an additional 76,639 shares in the last quarter. Finally, Prosperity Wealth Management Inc. purchased a new position in shares of Invitae in the fourth quarter valued at $144,000. 61.28% of the stock is owned by hedge funds and other institutional investors.

About Invitae

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.